We really don't know what we have. How Far along are the kts. Why when the last BOD needed a win so badly did they not even peep about details of Exosomes. Quiet in the past had not been good for PPHM , IP. Hope we have a tiger here but not enough details to know. Hope this time it's different.
On the PS targeting again what don't we know. What are the intentions with regard to NCCN/MSK.
I don't know what we have and in both cases who is interested from current market holders in those spaces.
$200B, BULL, as of Nov 2016, Illumina remains the leader in its industry, and management believes that the genomic testing market could eventually exceed $20 billion in annual sales.”
Market Data 
Markets 
AI
